Nadia Haj Mohammad

Nadia Haj Mohammad serves as an Assistant Professor of Medical Oncology at Utrecht University, working at the UMC Utrecht since 2014. She specializes in gastroesophageal and primary liver cancers, holding leadership roles as national PI for the phase 2 LyRICX study in metastatic gastroesophageal cancer and local PI for multiple investigator-initiated and sponsor-investigated studies focused on upper digestive tract and primary liver tumors.

Her educational background includes:

• Pharmacy degree from Utrecht University (2001)
• Medical studies at the University of Amsterdam (commenced 2000)
• Combined medical oncology training at the Academic Medical Center (AMC) with PhD research on clinical outcomes for gastroesophageal and pancreatic carcinoma

Her research program targets improved surveillance, diagnostics, treatment, and outcomes for primary liver tumor patients through interdisciplinary and international collaboration. She focuses on clinical translation of findings for hepatocellular carcinoma and cholangiocarcinoma, with emphasis on treatment efficacy and patient-centered care pathways in gastrointestinal oncology.

Recent 2025 publications demonstrate her dual research thrusts: analyzing treatment protocol impacts on survival outcomes in esophageal cancer and developing patient preference frameworks for oncology trial design. These works reflect her commitment to evidence-based optimization of gastrointestinal cancer management through rigorous clinical investigation.

Scientific recognition:

• No specific awards documented in source materials

Dr. Haj Mohammad actively leads national research initiatives including the LyRICX trial and multiple upper GI/liver tumor studies. Her grant portfolio encompasses investigator-initiated trials and industry-sponsored collaborations focused on treatment optimization for advanced gastrointestinal malignancies.

She directs the Primary Liver Tumors research group at UMC Utrecht, serves on the Dutch Upper GI Cancer group board, and contributes to national guidelines for hepatocellular carcinoma and bile duct carcinoma. Her collaborative network spans national clinical guideline committees and international oncology research consortia focused on improving liver and upper GI cancer outcomes.